A phase I study of weekly topotecan and paclitaxel in previously treated epithelial ovarian carcinoma patients

Gynecologic Oncology

Volumn 87, Issue 2, 2002, Pages 171-177

  Homesley, H ^a   Benigno, B ^b   Williams, J ^c   Vaccarello, L ^d  

^a Brookview Research Inc   (United States)

^b Southeastern Gynecologic Oncology   (United States)

^c South Carolina Oncology Associates   (United States)

^d Gynecologic Oncology and Pelvic Surgery   (United States)

Author keywords

Cancer antigen 125; Ovarian cancer; Paclitaxel; Topoisomerase I; Topotecan

Indexed keywords

CA 125 ANTIGEN; PACLITAXEL; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 11; TOPOTECAN;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ANTIGEN DETECTION; ARTICLE; BLOOD TRANSFUSION; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE CALCULATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; LONG TERM CARE; MAXIMUM TOLERATED DOSE; NAUSEA AND VOMITING; NEUTROPENIA; OVARY CARCINOMA; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TOXICITY;

EID: 0036927307     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.2002.6811     Document Type: Article

References (39)

1. Ozols RF, Bundy BN, Fowler J, Clarke-Pearson D, Mannel R, Hartenbach EM, Baergen R. Randomized phase III study of cisplatin (CIS)/paclitaxel (PAC) versus carboplatin (CARBO)/PAC in optimal stage III epithelial ovarian cancer (OC): A Gynecologic Oncology Group trial (GOG 158). Proc Am Soc Clin Oncol 1999;18:356a [abstract].
2. Berek JS, Bertelsen K, du Bois A, Brady MF, Carmichael J, Eisenhauer EA, Gore M, Grenman S, Hamilton TC, Hansen SW, Harper PG, Horvath G, Kaye SB, Luck HJ, Lund B, McGuire WP, Neijt JP, Ozols RF, Parmar MK, Piccart-Gebhart MJ, van Rijswijk R, Rosenberg P, Rustin GJ, Sessa C, Thigpen JT, Trope C, Tuxen MK, Vergote I, Vermorken JB, Willemse PH. Advanced epithelial ovarian cancer: 1998 Consensus statements. Ann Oncol 1999;10(Suppl. 1):87-92.
3. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
4. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M. Comparison of combination therapy with paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with suboptimal stage III and stage IV ovarian cancer: A Gynecologic Oncology Group study. Semin Oncol 1997;24(Suppl. 2):S2-13-S2-16.
5. Omura G, Blessing JA, Ehrlich CE, Miller A, Yordan E, Creasman WT, Homesley HD. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group study. Cancer 1986;57:1725-30.
6. Friedlander M, Millward MJ, Bell D, Bugat R, Harnett P, Moreno JA, Campbell L, Varette C, Ripoche V, Kayitalire L. A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer. Ann Oncol 1998;9:1343-5.
7. Muggia FM, Hainsworth JD, Jeffers S, Miller P, Groshen S, Tan M, Roman L, Uziely B, Muderspach L, Garcia A, Burnett A, Greco FA, Morrow CP, Paradiso LJ, Liang LJ. Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997;15:987-93.
8. Goldberg JM, Piver MS, Hempling RE, Recio FO. Paclitaxel and cisplatin combination chemotherapy in recurrent epithelial ovarian cancer. Gynecol Oncol 1996;63:312-7 (doi:10.1006/gyno.1996.0328).
9. Hoskins PJ, McMurtrie E, Swenerton KD. A phase II trial of intravenous etoposide (VP-16-213) in epithelial ovarian cancer resistant to cisplatin or carboplatin: Clinical and serological evidence of activity. Int J Gynecol Cancer 1992;2:35-40.
10. Hoskins P, Eisenhauer E, Beare S, Roy M, Drouin P, Stuart G, Bryson P, Grimshaw R, Capstick V, Zee B. Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: A National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 1998;16:2233-7.
11. Kudelka AP, Tresukosol D, Edwards CL, Freedman RS, Levenback C, Chantarawiroj P, Gonzalez de Leon C, Kim EE, Madden T, Wallin B, Hord M, Verschraegen C, Raber M, Kavanagh JJ. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 1996;14:1552-7.
12. Creemers GJ, Bolis G, Gore M, Scarfone G, Lacave AJ, Guastalla JP, Despax R, Favalli G, Kreinberg R, Van Belle S, Hudson I, Verweij J, ten Bokkel Huinink WW. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: Results of a large European phase II study. J Clin Oncol 1996;14:3056-61.
13. Bookman MA, Malmström H, Bolis G, Gordon A, Lissoni A, Krebs JB, Fields SZ. Topotecan for the treatment of advanced epithelial ovarian cancer: An open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 1998;16:3345-52.
14. ten Bokkel Huinink W, Gore M, Carmichael J, Gordon A, Malfetano J, Hudson I, Broom C, Scarabelli C, Davidson N, Spanczynski M, Bolis G, Malmström H, Coleman R, Fields SC, Heron JF. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997;15:2183-93.
15. ten Bokkel Huinink W, Carmichael J, Armstrong D, Gordon A, Malfetano J. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma. Semin Oncol 1997;24(Suppl. 5):S5-19-S5-25.
16. Swisher EM, Mutch DG, Rader JS, Elbendary A, Herzog TJ. Topotecan in platinum- and paclitaxel-resistant ovarian cancer. Gynecol Oncol 1997; 66:480-6 (doi:10.1006/gyno.2001.6435).
17. McGuire WP, Blessing JA, Bookman MA, Lentz SS, Dunton CJ. Topo-tecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 2000;18:1062-7.
18. Homesley HD, Hall DJ, Martin DA, Lewandowski GS, Vaccarello L, Nahhas WA, Suggs CL, Penley RG. A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients. Gynecol Oncol 2001;83:394-9 (doi:10.1006/gyno.2001.6435).
19. Markman M, Hall J, Spitz D, Weiner S, Carson L, Van Le L, Baker M. Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. J Clin Oncol 2002;20:2365-9.
20. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, Gianni L, Myles J, van der Burg ME, Kerr I, Vermorken JB, Buser K, Colombo N. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion. J Clin Oncol 1994;12:2654-66.
21. Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC. Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 1997;89:1138-47.
22. Wall JG, Burris HA III, Von Hoff DD, Rodriguez G, Kneuper-Hall R, Shaffer D, O'Rourke T, Brown T, Weiss G, Clark G, McVea S, Brown J, Johnson R, Friedman C, Smith B, Mann WS, Kuhn J. A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days. Anticancer Drugs 1992;3:337-45.
23. van Warmerdam LJ, ten Bokkel Huinink WW, Rodenhuis S, Koier I, Davies BE, Rosing H, Maes RA, Beijnen JH. Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion. J Clin Oncol 1995;13:1768-76.
24. Hochster H, Speyer J, Wadler S, Runowicz C, Wallach R, Oratz R, Chachoua A, Sorich J, Taubes B, Ludwig E, Broom C. Activity of topotecan (TPT) 21-day infusion in platinum-treated ovarian cancer and pharmacodynamics of topo-1 depletion (a NYGOG study). Ann Oncol 1996;7(Suppl. 5):69 [abstract].
25. Markman M, Blessing JA, Alvarez RD, Hanjani P, Waggoner S, Hall K. Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: A Gynecologic Oncology Group study. Gynecol Oncol 2000;77:112-5 (doi:10.1006/gyno.2000. 5755).
26. Brown JV III, Peters WA III, Rettenmaier MA, Karlan BY, Dillman RA, Smith MR, Drescher CW, Micha JP. A phase I trial of a 3-day topotecan q 21 days for recurrent epithelial cancers of the ovary, fallopian tube, and peritoneum. Gynecol Oncol 2000;79:495-8 (doi:10.1006/gyno.2000. 6006).
27. Rose PG, Gordon NH, Fusco N, Fluellen L, Rodriguez M, Ingalls ST, Hoppel CL. A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma. Gynecol Oncol 2000;78:228-34 (doi:10.1006/ gyno.2000.5844).
28. Rowinsky EK, Grochow LB, Hendricks CB, Ettinger DS, Forastiere AA, Hurowitz LA, McGuire WP, Sartorius SE, Lubejko BG, Kaufmann SH, Donehower RC. Phase I and pharmacologic study of topotecan: A novel topoisomerase I inhibitor. J Clin Oncol 1992;10:647-56.
29. Jagasia MH, Langer CJ, Johnson DH, Yunus F, Rodgers JS, Schlabach LL, Cohen AG, Shyr Y, Carbone DP, Devore RF. Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: A multicenter phase II study. Clin Cancer Res 2001;7:68-73.
30. von Pawel J, Gatzemeier U, Pujol JL, Moreau L, Bildat S, Ranson M, Richardson G, Steppert C, Riviere A, Camlett I, Lane S, Ross G. Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol 2001;19:1743-9.
31. Dowlati A, Levitan N, Gordon NH, Hoppel CL, Gosky DM, Remick SC, Ingalls ST, Berger SJ, Berger NA. Phase II and pharmacokinetic/pharmacodynamic trial of sequential topoisomerase I and II inhibition with topotecan and etoposide in advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 2001;47:141-8.
32. Dunphy FR, Dunleavy TL, Harrison BR, Cantrell CL, Visconti JL, Pincus SM, Richart JM, Petruska PJ. Phase I dose escalation study of topotecan combined with alternating schedules of paclitaxel and carboplatin in advanced solid tumors. Ann Oncol 2001;12:549-55.
33. Bowman A, Rye T, Ross G, Wheatley A, Smyth JF. Effective dosing of topotecan with carboplatin in relapsed ovarian cancer: A phase I/II study. J Clin Oncol 2001;19:3255-9.
34. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001;19:3312-22.
35. Bookman MA. Developmental chemotherapy in advanced ovarian cancer: Incorporation of topoisomerase-I inhibitors and perspective of the Gynecologic Oncology Group. Int J Gynecol Cancer 2001;11(Suppl. 1):42-51.
36. Takeuchi S, Dobashi K, Fujimoto S, Tanaka K, Suzuki M, Terashima Y, Hasumi K, Akiya K, Negishi Y, Tamaya T, Umessaki N, Sekiba K, Aono T, Nakano H, Noda K, Shiota M, Yakushiji M, Sugiyama T, Hashimoto M, Yajima A, Takamizawa H, Sonoda A, Takeda Y, Tomoda Y, Ohta M, Ozaki M, Hirabayashi K, Hiura M, Hatae M, Mishigaki K, Taguchi T. A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer. Research Groups of CPT-11 in Gynecologic Cancers. Gan To Kagaku Ryoho 1991; 18:1681-9 [translation].
37. Muggia FM, Braly PS, Brady MF, Sutton G, Niemann TH, Lentz SL, Alvarez RD, Kucera PR, Small JM. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 2000;18:106-15.
38. Sun W, Stevenson JP, Gallagher M, Giantonio B, Algazy K, Haller D, Vaughn D, Raskay BJ, O'Dwyer PJ. A phase I trial of topotecan and gemcitabine administered weekly for 3 consecutive weeks to patients with advanced tumors. Cancer 2001;92:414-9.
39. Bolis G, Scarfone G, Tateo S, Mangili G, Villa A, Parazzini F. Response and toxicity to topotecan in sensitive ovarian cancer cases with small residual disease after first-line treatment with carboplatinum and paclitaxel. Gynecol Oncol 2001;80:13-5 (doi:10.1006/ gyno.2000.5995).